Cerebrolysin is a porcine brain-derived peptide mixture used clinically in Europe and Asia to support recovery from stroke, traumatic brain injury, and neurodegenerative disease by mimicking the brain's own growth factors.
What it does
Cerebrolysin is made by enzymatically breaking down pig brain tissue into a mixture of small neuropeptides (protein fragments under 10 kDa — small enough to cross the blood-brain barrier, the tightly regulated gateway between the bloodstream and brain) and free amino acids. These peptides act like naturally occurring neurotrophic factors — proteins the brain uses to keep neurons alive and connected. Specifically, they mimic BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), binding to TrkB and TrkA receptors on neurons to promote survival, dendritic branching (the growth of neuron 'branches' that form connections), and synaptic plasticity (the brain's ability to strengthen or reorganize connections) Konrad 2023.
At the cellular level, Cerebrolysin activates the PI3K/AKT pathway — a pro-survival signaling cascade that inactivates a pro-death protein called BAD and suppresses caspase-3, an enzyme that executes programmed cell death. The net effect is reduced neuronal apoptosis (cell death) following ischemic injury Li 2019. It also upregulates synapsin and synaptophysin, proteins that physically build and stabilize synaptic connections, and enhances long-term potentiation (LTP), the electrophysiological process underlying memory formation Konrad 2023.
Cerebrolysin also dials down neuroinflammation — it reduces microglial activation (microglial cells are the brain's resident immune cells, which can cause collateral damage when chronically overactive) and lowers levels of pro-inflammatory cytokines in the central nervous system Aruna 2020.
What the evidence shows
Stroke recovery Moderate human trial evidence; multiple RCTs, though some with methodological limitations
Several randomized controlled trials have examined Cerebrolysin in acute and subacute stroke. A prospective double-blind study found Cerebrolysin outperformed other peptide preparations in functional outcomes following embolic stroke Li 2019. An ongoing trial is evaluating it as an add-on therapy specifically for basilar artery occlusion — a severe and often fatal stroke subtype NCT06489925. Active trials are also examining its effect on post-stroke aphasia (language loss) NCT06897176. The evidence base is stronger than most nootropics but falls short of the large-scale, multi-center trials that define first-line stroke drugs.
Traumatic brain injury (TBI) Moderate — two systematic reviews and meta-analyses of controlled trials
Two separate systematic reviews and meta-analyses found Cerebrolysin associated with improved functional outcomes in TBI patients Konrad 2023, Fariborz 2019. Rodent data showed it reduces astrogliosis (scar-forming glial cell proliferation), axonal injury, and promotes neurogenesis (new neuron growth) after closed head injury Yanlu 2019. Preclinical work also demonstrates a neuroprotective effect in models combining TBI with sleep deprivation, including synergy with co-administered agents Aruna 2020. The human trial quality is variable — pooled sample sizes are moderate and protocols differ across studies — so the meta-analytic findings are encouraging but not definitive.
Seizure-related neuronal protection Early-stage — rodent data only
In a pilocarpine-induced seizure model in rats, Cerebrolysin reduced hippocampal neuron death after status epilepticus Hyeon 2020. This is relevant because seizures cause excitotoxic (overstimulation-driven) cell death in the hippocampus, the brain region most critical for memory. No controlled human trials exist for this indication, and notably, seizure induction is a known adverse effect of Cerebrolysin at higher doses, making this a complicated area.
ICU delirium Investigational — active trial, no results yet
A registered trial is evaluating Cerebrolysin in critically ill patients with delirium — acute-onset confusion common in ICU settings and associated with long-term cognitive impairment NCT06677502. No results are published yet. The rationale is Cerebrolysin's anti-inflammatory and neuroprotective profile, but this indication remains speculative until data emerge.
How it's used
In clinical trials and approved medical use, Cerebrolysin is administered by injection — either intramuscular (IM) or intravenous (IV slow infusion). It is not available orally because the peptides are destroyed by digestion. Courses typically run 10–20 consecutive days. Low-end protocols use 5 mL IM daily; moderate protocols use 10 mL IM daily; acute stroke protocols in trials have used up to 30 mL IV daily. Active fragments have a half-life of roughly 6 hours. Morning administration is standard in clinical protocols. In self-reported use outside clinical settings, lower IM doses (5–10 mL per course) are most commonly described. Because this is a porcine-derived injectable, sterile technique and sourcing from pharmaceutical-grade suppliers matter significantly.
Side effects and safety
In clinical trials, mild side effects include dizziness, headache, and injection site reactions. Moderate effects — agitation, insomnia, nausea, and sweating — occur less frequently and are generally dose-dependent. The most serious risks are seizure induction (particularly in individuals with pre-existing epilepsy, where it may lower the seizure threshold) and anaphylaxis in people with porcine (pork) allergies. Absolute contraindications include status epilepticus, severe renal impairment, pregnancy, and known hypersensitivity. Long-term safety data in healthy people without neurological injury are essentially absent — nearly all trial populations are patients with acute brain injury or neurodegenerative disease. Whether repeated courses carry cumulative risk is unknown.
Bottom line
Cerebrolysin has a more substantial evidence base than most peptides discussed in self-optimization contexts — it's an approved drug in multiple countries with meta-analyses supporting use in TBI and stroke recovery. That said, the trials are heterogeneous and most involve acute neurological injury, not healthy cognitive enhancement. People considering it for neuroprotection after injury have a reasonable evidence rationale; those seeking general cognitive enhancement are extrapolating well beyond the data.